Stephen Mullennix

2018

In 2018, Stephen Mullennix earned a total compensation of $4.3M as Chief Operating Officer and Interim Chief Financial Officer at UroGen Pharma Ltd..

Compensation breakdown

Bonus$70,000
Non-Equity Incentive Plan$223,400
Option Awards$2,552,946
Salary$359,754
Stock Awards$1,102,893
Other$575
Total$4,309,568

Mullennix received $2.6M in option awards, accounting for 59% of the total pay in 2018.

Mullennix also received $70K in bonus, $223.4K in non-equity incentive plan, $359.8K in salary, $1.1M in stock awards and $575 in other compensation.

Rankings

In 2018, Stephen Mullennix's compensation ranked 2,521st out of 14,244 executives tracked by ExecPay. In other words, Mullennix earned more than 82.3% of executives.

ClassificationRankingPercentile
All
2,521
out of 14,244
82nd
Division
Manufacturing
929
out of 5,759
84th
Major group
Chemicals And Allied Products
318
out of 2,122
85th
Industry group
Drugs
258
out of 1,811
86th
Industry
Pharmaceutical Preparations
201
out of 1,385
86th
Source: SEC filing on April 26, 2019.

Mullennix's colleagues

We found six more compensation records of executives who worked with Stephen Mullennix at UroGen Pharma Ltd. in 2018.

2018

Ron Bentsur

UroGen Pharma Ltd.

Chief Executive Officer

2018

Gil Hakim

UroGen Pharma Ltd.

Former President

2018

Gary Titus

UroGen Pharma Ltd.

Chief Financial Officer

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Peter Pfreundschuh

UroGen Pharma Ltd.

Chief Financial Officer

2018

Mark Schoenberg

UroGen Pharma Ltd.

Chief Medical Officer

News

In-depth

You may also like